Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 2/20 | 0.32 |
| ▸ | AXL | P30530 | 1/20 | 0.32 |
| ▸ | METAP2 | P50579 | 1/20 | 0.31 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.30 |
| ▸ | IDO1 | P14902 | 1/20 | 0.30 |
| ▸ | TDO2 | P48775 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30468824 | 1.00 | HTT (0.33) | HTTPTK2NOS1AXLMETAP2 | |
| SCHEMBL29366423 | 0.78 | HTT (0.38) | HTTPTK2NOS1AXLMETAP2 | |
| SCHEMBL22805892 | 0.78 | HTT (0.38) | HTTPTK2NOS1AXLMETAP2 | |
| SCHEMBL26650949 | 0.77 | AXL (0.39) | HTTPTK2NOS1AXLMETAP2 | |
| SCHEMBL29831022 | 0.77 | AXL (0.39) | HTTPTK2NOS1AXLMETAP2 | |
| SCHEMBL22805867 | 0.75 | NOS1 (0.38) | HTTPTK2NOS1AXLIDO1 | |
| SCHEMBL31393062 | 0.75 | NOS1 (0.38) | HTTPTK2NOS1AXLIDO1 | |
| SCHEMBL22805267 | 0.70 | HTT (0.38) | HTTPTK2NOS1AXLMETAP2 | |
| SCHEMBL29366601 | 0.70 | HTT (0.38) | HTTPTK2NOS1AXLMETAP2 | |
| SCHEMBL20656567 | 0.70 | ALDH1A1 (0.39) | HTTTRPA1IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260007678-A1 | COMBINATION OF ALLOSTERIC AND ORTHOSTERIC EGFR INHIBITORS FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE INC. (US) | 2026-01-08 | — | — | US | disclosed |
| US-20250313565-A1 | NEW INDAZOLE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2025-10-09 | — | — | US | disclosed |
| EP-4522113-A1 | COMBINATION OF ALLOSTERIC AND ORTHOSTERIC EGFR INHIBITORS FOR THE TREATMENT OF CANCER | F. Hoffmann-La Roche AG (CH) | 2025-03-19 | — | — | EP | disclosed |
| EP-4522617-A1 | NEW INDAZOLE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2025-03-19 | — | — | EP | disclosed |
| US-20240018154-A1 | NEW INDAZOLE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2024-01-18 | — | — | US | disclosed |
| US-20240018154-A1 | NEW INDAZOLE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2024-01-18 | — | — | US | disclosed |
| US-20240018154-A1 | NEW INDAZOLE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2024-01-18 | — | — | US | disclosed |
| US-20240002390-A1 | NEW INDAZOLE ACETYLENE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2024-01-04 | — | — | US | disclosed |
| WO-2023217923-A1 | NEW INDAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023217924-A1 | COMBINATION OF ALLOSTERIC AND ORTHOSTERIC EGFR INHIBITORS FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023217923-A1 | NEW INDAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023217924-A1 | COMBINATION OF ALLOSTERIC AND ORTHOSTERIC EGFR INHIBITORS FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2023-11-16 | — | — | WO | disclosed |
| EP-4255906-A1 | NEW INDAZOLE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2023-10-11 | — | — | EP | disclosed |
| EP-4255908-A1 | NEW INDAZOLE ACETYLENE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2023-10-11 | — | — | EP | disclosed |
| CN-116600806-A | Indazole derivatives | 豪夫迈·罗氏有限公司 | 2023-08-15 | — | — | CN | disclosed |
| CN-116490182-A | Indazole acetylene derivatives | 豪夫迈·罗氏有限公司 | 2023-07-25 | — | — | CN | disclosed |
| WO-2022117477-A1 | NEW INDAZOLE ACETYLENE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2022-06-09 | — | — | WO | disclosed |
| WO-2022117477-A1 | NEW INDAZOLE ACETYLENE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2022-06-09 | — | — | WO | disclosed |
| WO-2022117487-A1 | NEW INDAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2022-06-09 | — | — | WO | disclosed |
| WO-2022117487-A1 | NEW INDAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2022-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018154-A1 | NEW INDAZOLE DERIVATIVES | CYP3A43, CYP3A4, CYP3A5 | HTT 2957/4885PTK2 3512/4885NOS1 840/4885 |
| US-20260007678-A1 | COMBINATION OF ALLOSTERIC AND ORTHOSTERIC EGFR INHIBITORS FOR THE TREATMENT OF CANCER | EGFR, ERBB2, ERBB3 | HTT 1940/4885PTK2 112/4885NOS1 4782/4885 |
| US-20250313565-A1 | NEW INDAZOLE DERIVATIVES | CYP3A43, ABCB11, CYP3A7 | HTT 3227/4885PTK2 2906/4885NOS1 768/4885 |
| US-20240002390-A1 | NEW INDAZOLE ACETYLENE DERIVATIVES | NAT1, SIRT3, HDAC11 | HTT 2891/4885PTK2 2665/4885NOS1 1222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.